Applications of (5R,6S)-6-[(1R)-1-[[(1,1-Dimethylethyl)Dimethylsilyl]Oxy]Ethyl]-7-Oxo-3-[(2R)-Tetrahydro-2-Furanyl]-4-Thia-1-Azabicyclo[3.2.0]Hept-2-Ene-2-Carboxylic Acid 2-Propenyl Ester in Industrial Manufacturing

As one of the key side-chain protected intermediates for advanced β-lactam development, this compound is an essential building block in several specialized pharmaceutical manufacturing processes. Downstream applications capitalize on its specific stereochemistry and protecting groups to enable controlled conversion in highly regulated production settings. Below we detail its principal industrial uses in genuine commercial sectors, with precise formulation, process, compliance, and end product information.

1. Sterile Injectable Cephalosporin APIs

Pharmaceutical manufacturers utilize this intermediate during the synthesis of injectable third-generation cephalosporin actives where strict retention of β-lactam ring integrity is required. Silyl ether and tetrahydrofuran groups provide temporal protection during acylation and deprotection steps critical to the final compound yield and purity. Material addition occurs during semi-synthetic transformations proceeding to the active nucleus.

Industry compliance standards

• Current Good Manufacturing Practice (cGMP, 21 CFR Parts 210/211)
• ICH Q7: Good Manufacturing Practice for APIs
• European Pharmacopeia (Ph. Eur. monographs for cephalosporin derivatives)
• USP-NF General Chapters for Sterile Drug Substances

Typical usage ratio

• Batch-dependent, typically 1-1.1 molar equivalents versus acyl chloride coupling partner; actual quantity varies based on the target yield, with process validation determining precise ratio for API scale batches ranging 5–50 kg.

Downstream process integration

• Introduced in the protected nucleus synthesis stage prior to deprotection and purification via crystallization, with analytical checks for residual silanols during each intermediate step.

Final product types

• Sterile, injectable cephalosporin antibiotics including cefotaxime, ceftriaxone, and analogues produced after final salt formation and lyophilization.

2. Oral Cephalosporin Drug Intermediates

Producers of solid oral β-lactam medications source this raw material for semi-synthetic modifications where stability through multiple processing environments is critical. Its selectivity during side chain elongation supports the synthesis of orally bioavailable cephalosporins, and it is charged at the protected stage to resist hydrolytic degradation until targeted deprotection.

Industry compliance standards

• International Conference on Harmonisation (ICH) Q11: Development and Manufacture of Drug Substances
• Japanese Pharmacopoeia (JP) for antimicrobial intermediates
• FDA Guidance for Industry: ANDAs for Oral β-lactam Drugs
• EudraLex Volume 4 – GMP Guidelines (Part II APIs)

Typical usage ratio

• Standardized at 0.95–1.10 molar equivalents; process engineers adjust for batch scale losses and impurity controls, documented during technical transfer and scale-up phases.

Downstream process integration

• Material forms the key intermediate in side-chain substitution reactions prior to azide reduction or further esterification; integrated via controlled addition in reactor trains designed for oral cephalosporin synthesis lines.

Final product types

• Oral tablets, capsules, and pediatric oral suspensions of cephalosporin antibiotics such as cefuroxime axetil and related derivatives.

3. Active Ester for β-Lactam Prodrug Synthesis

Industrial manufacturers leverage the propenyl ester group for the synthesis of β-lactam prodrugs where controlled hydrolysis rates are needed in vivo. The raw material enters as a protected intermediate, giving process chemists latitude to tune prodrug pharmacokinetics by alteration of the downstream esterification or hydrolysis conditions, critical for oral and parenteral dosage forms.

Industry compliance standards

• FDA 21 CFR Part 314 (Applications for FDA Approval to Market a New Drug)
• WHO TRS 986 Annex 2: GMP for Pharmaceutical Products
• ICH Q3C: Impurities: Guideline for Residual Solvents
• ISO 9001:2015 (Quality Management Systems for Pharma)

Typical usage ratio

• Normally 1.0–1.3 molar equivalents, with minor excess to account for incomplete reaction and removal of byproducts, especially when targeting ester solvolysis conversion profiles.

Downstream process integration

• Added following initial cephalosporin core assembly and used in the selective formation of prodrug linkages before deprotection; hydrolysis monitored via HPLC to ensure desired prodrug activation kinetics.

Final product types

• Prodrug antibiotic APIs such as esterified cefpodoxime, pivoxil, and related modified β-lactams for improved oral absorption or extended-release formulations.

4. Research Reference Standards and Analytical Reagents

Analytical laboratories and pharmaceutical research centers acquire this material in small quantities to serve as certified reference standards for method development, impurity profiling, and analytical control during β-lactam process validation. Its defined stereochemistry and protecting groups allow selective tracking of process intermediates and degradation products.

Industry compliance standards

• Pharmacopoeia standards for reference substances (USP RS, EP CRS)
• OECD Good Laboratory Practice (GLP)
• ISO/IEC 17025:2017 for Testing and Calibration Laboratories
• FDA 21 CFR Part 58: GLP for Nonclinical Laboratory Studies

Typical usage ratio

• Trace levels (1–50 mg per analytical batch); quantity determined by validated method sensitivity, reference solution stability, and calibration range requirements.

Downstream process integration

• Supplied as analytical markers or spiking standards in method development, process QC, and stability studies at API and finished product analysis stages.

Final product types

• Pharmaceutical reference solutions, calibration curves for HPLC/LC-MS, and spike recovery kits for quality assurance laboratories.